The year’s crop of US drug approvals won’t rival past vintages for quantity. But of the 45 drugs cleared for use by the FDA in 2022,...
Catherine Isted has stepped down as chief executive of UK biotech ReNeuron with immediate effect, with board member The post Restructuring announced at...
Immunobiology biotech Equillium announced a “mutual termination” of an anticipated merger with Rich Heyman-chaired Metacrine a little over three months...
Molecular predictors of response to obesity treatment are key in combating the obesity epidemic. A blood test being developed by Phenomix Sciences in collaboration...
Welcome to TDR’s review of the Top 5 Psychedelic Developments for the week of December 19. Aside from presenting a synopsis of events, we provide market...
There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T The post After a slow start for expensive...
To conclude pharmaphorum’s look back at day one of The Economist’s 8th Annual World Cancer Series congress in The post Economist Impact: World Cancer...
It Was Always About Control Authored by Richard Kelly via The Brownstone Institute, Early on in March 2020 I was leery of the hysteria surrounding...
It seems like a slam dunk. Why not repurpose already approved or well-studied drug candidates for conditions where treatments are desperately needed? Wouldn’t...
As the COVID pandemic broke open quite clearly, never has there been a greater need for innovation to treat psychological disorders. With the World Health...
Social isolation and loneliness in aging adults have been linked to numerous physical and mental health ailments. Teaching students how to listen deeply...
Taking a brief look back to pharmaphorum’s coverage of Day One of The Economist’s 8th Annual World Cancer The post Economist Impact: World Cancer Series...
Amicus Therapeutics could be just weeks away from getting EU approval for its new Pompe disease therapy Pombiliti The post CHMP backs Amicus’ therapy...
MUSC Hollings Cancer Center oncologists found that using a combination monoclonal antibody (tixagevimab-cilgavimab) against the SARS-CoV-2 spike protein...
After missing its primary goal in Phase IIa trials for its long Covid drug, Axcella Health announced Wednesday that it’s cutting 85% of its workforce,...
New AI technology holds the key to improving knowledge exchange and implementation in real-world clinical practice.
Moderna and Merck hailed preliminary results from a combination therapy as a breakthrough, but there are important nuances to consider.
A large study that focused on whether exercise and mindfulness training could boost cognitive function in older adults found no such improvement following...
Part II: Leaders in healthcare marketing and communications discuss the looming concerns regarding the healthcare ecosystem.
Tessera’s technology, called RNA gene writers, is based upon a type of mobile element called a non-LTR retrotransposon. These use a mechanism to write...
A weekly stock market preview and the data that will impact the tape. Sunday Evening Futures Weekend News And Developments 2 venture capital investors...
A review of the latest executive moves in the pharma industry over the past several months.
FDA Says Ivermectin Doesn't Work Against COVID-19 But Points To Studies That Show It Does Authored by Zachary Stieber via The Epoch Times...
Most young people regard reining in the big social media platforms as only part of the solution to the ‘relentless stream’ of abuse and shaming they...
Quinn: We Are Trapped In 'A Truman Show' Directed By Psychopaths Authored by Jim Quinn via The Burning Platform blog, “Whether in actual...
By Benjamin Boettner / Wyss Institute Communications Credit: E. Super / Wyss Institute at Harvard University By Benjamin Boettner / Wyss Institute Communications...
A professor of psychology offers an extraordinary insight into what it is like to be diagnosed with this frightening condition, and how she is dealing...
Enrolling for clinical trials has become more challenging in recent years, with trial competition, increasingly complex protocols, and The post Improving...
Scientists at Hong Kong University of Science and Technology came up with a technique to increase the efficiency and potentially the efficacy of mRNA therapeutics....
Wednesday afternoon, Gene editing company Intellia and eye disease company Iveric Bio announced that they had each raised $300 million by selling off some...